Hypertrophic pulmonary osteoarthropathy (HOA) is a condition associated with lung cancer and many other diseases. Pain associated with HOA can be disabling, unremitting, and refractory to conventional analgesic medications. We present a challenging case of HOA in a patient with nonsmall cell lung cancer and review specific therapies for management of HOA-related pain.
Martinez-LavinMVargasARivera-VinasM. Hyperthrophic osteoarthropathy: a palindrome with a pathogenic connotation. Curr Opin Rheumatol. 2008;20(1):88–91.
2.
Martinez-LavinMMatucci-CerinicMJajicIPinedaC. Hypertrhophi osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol. 1993;20(8):1386–1387.
3.
CastoriMSinibaldiLMingarelliRLachmanRSRimoinDLDallapiccolaB. Pachydermoperiostosis: an update. Clin Genet. 2005;68(6):477–486.
4.
NguyenSHojjatiM. Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy. Clin Rheumatol. 2011;30(1):7–13.
5.
Ángel-Moreno MarotoAMartínez-QuintanaESuárez-CastellanoLPérez-ArellanoJL. Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology (Oxford). 2005;44(10):1326–1327.
6.
FlavellG. Reversal of pulmonary hypertrophic osteoarthropathy by vagotomy. Lancet. 1956;270(6911):260–262.
7.
HuckstepRLBodkinPE. Vagotomy in hypertrophic pulmonary osteoarthropathy associated with bronchial carcinoma. Lancet. 1958;2(7042):343–345.
AtkinsonSFoxSB. Vascular endothelial growth factor (VEGF)-A and platelet derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721–728.
HaradaSNagyJASullivanKAInduction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest. 1994;93(6):2490–2496.
16.
UppalSDiggleCPCarrIMMutations in 15-hydroxyprostaglandin dehydrogenase cause primary hyperthrophic osteoartropathy. Nat Genet. 2008;40(6):789–793.
PinedaCJGuerraJJrWeismanMHResnickDMartinez-LavinM. The skeletal manifestations of clubbing: a study in patients with cyanotic congenital heart disease and hypertrophic osteoartropathy. Semin Arthritis Rheum. 1985;14(4):263–273.
20.
NaharIAl-ShemmeriMHussainM. Secondary hypertrophic osteoarthropathy: new insights on pathogenesis and management. Gulf J Oncolog. 2007;1(1):71–76.
21.
OoiASaadRAMoorjaniNAmerKM. Effective symptomatic relief of hypertrophic pulmonary osteoarthropathy by video-assisted thoracic surgery truncal vagotomy. Ann Thorac Surg. 2007;83(2):684–685.
22.
ArmstrongDJMcCauslandEMWrightGD. Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): two cases presenting as acute inflammatory arthritis. Description and review of the literature. Rheumatol Int.2007;27(4):399–402.
23.
AtkinsonMKMcElwainTJPeckhamMJThomasPP. Hypertrophic pulmonary osteoarthropathy in Hodgkin’s disease: reversal with chemotherapy. Cancer. 1976;38(4):1729–1734.
24.
KozakKRMilneGLMorrowJDCuiffoBP. Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2. Nat Clin Pract Rheumatol. 2006;2(8):452–456.
25.
LeungFWWilliamsAJFanP. Indomethacin therapy for hypertrophic pulmonary osteoarthropathy in patients with bronchogenic carcinoma. West J Med. 1985;142(3):345–347.
26.
BlackwellNBanghamLHughesMMelzackDTrotmanI. Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac. Thorax. 1993;48(4):401.
27.
SpedenDNicklasonFFrancisHWardJ. The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA). Aust N Z J Med. 1997;27(3):307–310.
28.
SuzumaTSakuraiTYoshimuraGPamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs. 2001;12(9):731–734.
29.
GarskeLABellSC. Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathyin cystic fibrosis. Chest. 2002;121(4):1363–1364.
30.
AmitalHApplbaumYHVasilievLRubinowA. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol. 2004;23(4):330–332.
31.
MauricioOFrancisLAtharUShahCChaudharyMGajraA. Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates. J Thorac Oncol. 2009; 4(2):260–262.
32.
YaoQAltmanRDBrahnE. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum. 2009;38(6):458–466.
JayakarBAAbelsonAGYaoQ. Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature. Semin Arthritis Rheum. 2011.
35.
Guyot-DrouotMHSolau-GervaisECortetBRheumatologic manifestations of pachydermoperiostosis and preliminary experience with bisphosphonates. J Rheumatol. 2000;27(10):2418–2423.
36.
ChennuruSKoduriJBaumannMA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J. 2008;38(8):635–637.
37.
DunstanCRFelsenbergDSeibelMJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007;4(1):42–55.
38.
ChangJTGreenLBeitzJ. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349(17):1676–1679.
HillnerBEIngleJNChlebowskiRTAmerican society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–4957.
41.
DimopoulosMAKastritisEBamiaCReduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117–120.
42.
DinerWC. Hypertrophic osteoarthropathy. Relief of symptoms by vagotomy in a patienh with pulmonary metastases from a lympho-epithelioma of the nasopharynx. JAMA.1962;181:555–557.
43.
TreasureT. Hypertrophic pulmonary osteoarthropathy and the vagus nerve: an historical note. J R Soc Med. 2006;99(8):388–390.
44.
HayashiMSekikawaASaijoATakadaWYamawakiIOhkawaS. Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma. Anticancer Res. 2005;25(3c):2435–2438.
45.
JohnsonSASpillerPAFaullCM. Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide. Thorax. 1997;52(3):298–299.
